

- [Home](#)
- [About us](#)
- [Contact us](#)
- [Advertise](#)
- [Media Kit](#)
- [Circulation](#)
- [Editorial Calendar 2017](#)
- [Electronic Issue](#)
- [Events](#)
- [PR Newswire](#)
- [Comments](#)
- [Posts](#)



- [Home](#)
- [About us](#)
- [Contact us](#)
- [Advertise](#)
- [Media Kit](#)



- [Circulation](#)
- [Editorial Calendar 2017](#)
- [Electronic Issue](#)
- [Events](#)
- [PR Newswire](#)

PR Newswire Feeds

PRNewswire
a CISION company

Cedrus Investments' Executive Director Olivia Lam Was Invited to Present at the Australia Biotech Invest in Melbourne on 24th October 2017

HONG KONG, Nov. 7, 2017 /PRNewswire/ -- Ms. Olivia Lam, Executive Director at [Cedrus Investments \("Cedrus"\)](#), was one of the three keynote speakers at the "Australia Biotech Invest" held in Melbourne on 24th October 2017. This annual event organized by AusBiotech, an Australian life sciences organization, attracted over 300 company executives in the industry and investors around the world attending this year. The Biotech Invest series, which also includes an annual investment conference in Hong Kong, has recently been expanded to Singapore and Shanghai in response to the rapidly-growing appetite for life sciences investments in Asia and the Greater China region. Since its inaugural conference in Hong Kong in 2013, Cedrus has

been working closely with AusBiotech to foster investments in the life sciences industry across borders.



Ms. Lam's presentation was focused on the opportunities and challenges encountered by Australian life sciences firms in raising capital, and forming partnerships and joint ventures with their counterparts or investors in the Greater China region. She also spoke about the usual structures of cross-border life sciences transactions and their respective advantages and disadvantages.

In recent years, Cedrus has been actively engaged in assisting life science companies from Australia and Europe to gain access to the Chinese market through private placements, identifying potential strategic business partners and investors, structuring and negotiating cross-border collaborations as well as setting up joint ventures.

[Cedrus' Chairman, Mr. Rani Jarkas](#) said, "We have seen growing interest from Chinese enterprises and investors to acquire life sciences technologies and products overseas, and the increased desire of Australian life science companies to build a presence in China, the second-largest biopharma market in the world. Through facilitating various deals, we have accumulated a lot of expertise and valuable experience in cross-border transactions and collaborations. We are happy to share them with investors and company executives, helping them achieve their strategic goals."

About Cedrus Investments

[Cedrus Investments](#) is a global boutique investment firm that offers expertise in [private wealth management](#), [asset management](#) and [financial advisory services](#) to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

Logo - <http://photos.prnasia.com/prnh/20150930/8521506461LOGO>

SOURCE Cedrus Investments

[Back](#) | [Next story: Atonarp Inc. and IMA Life \(a division of IMA S.p.A.\) enter supply agreement for pharmaceutical lyophilization applications](#)